It supports advanced research and helps scientists accelerate potential cures, drug discoveries and diagnostics research
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
Through this partnership, Premas will connect with genomics labs to provide automated NGS solutions
Co–Founder Sam Santhosh steps down as Chairman and Group CEO; will remain on Board of Directors. Co–founder Mahesh Pratapneni appointed Group CEO. Dr. Felix Olale appointed Chairman of the Board
Organizations to combine expertise to further develop AI/ML-powered drug design platform, delivering precise, effective, and life-changing medicines at scale
Arum's research focuses on the discovery of new chemical entities that will act as effective therapies for drug-resistant cancers
New line of Waters MaxPeak Premier columns further enhances the analysis by delivering 2x to 3x greater sensitivity than conventional steel columns
The facility will produce 150 million vaccine doses per year
Successful proposals will secure fully funded postdoctoral research positions
Machine learning approach to systems biology combined with ligand discovery platform
Subscribe To Our Newsletter & Stay Updated
